StockNews.AI
PIII
StockNews.AI
88 days

Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.

1. Wolf Haldenstein is investigating claims against PIII for misleading statements. 2. PIII reported negative $15 million EBITDA and operational losses in late 2024. 3. The stock fell by 46.4% after disappointing earnings release in November 2024. 4. A DOJ inquiry is ongoing regarding PIII's marketing practices. 5. Investors are encouraged to assist in the investigation.

4m saved
Insight
Article

FAQ

Why Very Bearish?

PIII's stock has suffered sharply due to poor financial results and ongoing investigations, similar to past cases where companies faced legal scrutiny and lost consumer trust.

How important is it?

The allegations and investigation raise significant concerns for investors, likely affecting PIII's stock price.

Why Short Term?

Immediate market reactions typically follow news of investigations and financial losses, impacting stock performance quickly.

Related Companies

CNCHUMUNH
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a distinguished law firm with over 125 years of history, announces it is investigating claims on behalf of investors of P3 Health Partners, Inc. (NASDAQ: PIII) (“P3” or the “Company”). (NASDAQ: PIII) Allegations and Investigation Focus: The investigation seeks to determine whether P3 Health Partners, and certain officers and directors, made false and misleading statements or omissions in violation of the federal securities laws. Triggering Events: 1.   November 12, 2024 – P3 reported disappointing financial results in its Form 10-Q filed with the United States Securities and Exchange Commission (SEC): $15 million in negative adjusted EBITDA from a write-down of midyear risk adjustment receivables.Additional $10 million in expenses from negative medical claims developments.Another $10 million due to network and operating expenses.Management said it would exit underperforming relationships and reduce its provider network by 20%.The stock fell from $19.50 to $10.45, between November 12 and November 14, 2025, a decline of 46.4%. 2.   March 28, 2025 – Annual Form 10-K disclosed: In June 2024, P3 received a civil investigative demand from the Department of Justice (DOJ).The inquiry relates to marketing practices and remuneration for Medicare Advantage brokers, agents, agencies and related third parties. Why Wolf Haldenstein Adler Freeman & Herz LLP? This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors. We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP. Contact Information: Firm: Wolf Haldenstein Adler Freeman & Herz LLP Primary Contact: Gregory Stone, Director of Case and Financial Analysis Email: gstone@whafh.com or classmember@whafh.com Phone: (800) 575-0735 or (212) 545-4774 This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Related News